CY1119748T1 - Υποκατασταθεντα 2-αλκυλ-1-οξο-ν-φαινυλ-3-ετεροαρυλ-1,2,3,4-τετραϋδροϊσοκινολιν-4-καρβοξαμιδια για ανθελονοσιακες θεραπειες - Google Patents

Υποκατασταθεντα 2-αλκυλ-1-οξο-ν-φαινυλ-3-ετεροαρυλ-1,2,3,4-τετραϋδροϊσοκινολιν-4-καρβοξαμιδια για ανθελονοσιακες θεραπειες

Info

Publication number
CY1119748T1
CY1119748T1 CY20171101092T CY171101092T CY1119748T1 CY 1119748 T1 CY1119748 T1 CY 1119748T1 CY 20171101092 T CY20171101092 T CY 20171101092T CY 171101092 T CY171101092 T CY 171101092T CY 1119748 T1 CY1119748 T1 CY 1119748T1
Authority
CY
Cyprus
Prior art keywords
oxo
phenyl
alkyl
substituted
etheroaryl
Prior art date
Application number
CY20171101092T
Other languages
Greek (el)
English (en)
Inventor
Rodney Kiplin Guy
Fangyi Zhu
Wendyam Armand GUIGUEMDE
David Floyd
Spencer KNAPP
Philip Stein
Steve CASTRO
Original Assignee
St. Jude Children’S Research Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by St. Jude Children’S Research Hospital filed Critical St. Jude Children’S Research Hospital
Publication of CY1119748T1 publication Critical patent/CY1119748T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CY20171101092T 2011-08-25 2017-10-20 Υποκατασταθεντα 2-αλκυλ-1-οξο-ν-φαινυλ-3-ετεροαρυλ-1,2,3,4-τετραϋδροϊσοκινολιν-4-καρβοξαμιδια για ανθελονοσιακες θεραπειες CY1119748T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161527594P 2011-08-25 2011-08-25
PCT/IB2012/054305 WO2013027196A1 (en) 2011-08-25 2012-08-24 Substituted 2-alkyl-1-oxo-n-phenyl-3-heteroaryl-1,2,3,4- tetrahydroisoquinoline-4-carboxamides for antimalarial therapies

Publications (1)

Publication Number Publication Date
CY1119748T1 true CY1119748T1 (el) 2018-06-27

Family

ID=47018313

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171101092T CY1119748T1 (el) 2011-08-25 2017-10-20 Υποκατασταθεντα 2-αλκυλ-1-οξο-ν-φαινυλ-3-ετεροαρυλ-1,2,3,4-τετραϋδροϊσοκινολιν-4-καρβοξαμιδια για ανθελονοσιακες θεραπειες

Country Status (19)

Country Link
US (1) US9416124B2 (enExample)
EP (1) EP2748147B1 (enExample)
JP (1) JP6035334B2 (enExample)
CN (1) CN103930404B (enExample)
BR (1) BR112014004437B1 (enExample)
CA (1) CA2846507C (enExample)
CY (1) CY1119748T1 (enExample)
DK (1) DK2748147T3 (enExample)
ES (1) ES2644082T3 (enExample)
HR (1) HRP20171567T1 (enExample)
HU (1) HUE034721T2 (enExample)
LT (1) LT2748147T (enExample)
ME (1) ME02908B (enExample)
PL (1) PL2748147T3 (enExample)
PT (1) PT2748147T (enExample)
RS (1) RS56544B1 (enExample)
SI (1) SI2748147T1 (enExample)
SM (1) SMT201700528T1 (enExample)
WO (1) WO2013027196A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111886225A (zh) * 2017-08-21 2020-11-03 纳维根公司 Arf6抑制剂及相关方法
EP3892332A1 (en) 2020-04-09 2021-10-13 University Of Kentucky Research Foundation New anti-malarial agents
CA3214899A1 (en) 2021-04-15 2022-10-20 Lutz Weber Isoquinoline derivatives for use as antiviral and antitumour agents
EP4074314A1 (en) 2021-04-15 2022-10-19 Valdospan GmbH Isoquinoline derivatives for use as antiviral and antitumour agents
AU2023363824A1 (en) 2022-10-17 2025-04-17 Rdp Pharma Ag Isoquinoline derivatives as protein degraders, e7 degraders, antivirals, tumor therapeutics and immune suppressives

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5409938A (en) * 1994-02-14 1995-04-25 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Antimalarial korupensamines and pharmaceutical compositions and medical uses thereof
US5639761A (en) * 1994-02-14 1997-06-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Antimalarial naphthylisoquinoline alkaloids and pharmaceutical compositions and medical uses thereof
US6921762B2 (en) * 2001-11-16 2005-07-26 Amgen Inc. Substituted indolizine-like compounds and methods of use
WO2004004727A1 (en) 2002-07-03 2004-01-15 Axys Pharmaceuticals, Inc. 3,4-dihydroisoquinolin-1-one derivatives as inducers of apoptosis
DE10237722A1 (de) * 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
DE10312963A1 (de) 2003-03-24 2004-10-07 Aventis Pharma Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
UY29440A1 (es) * 2005-03-25 2006-10-02 Glaxo Group Ltd Nuevos compuestos
RU2302417C1 (ru) * 2006-03-14 2007-07-10 Иващенко Андрей Александрович 1-оксо-3-(1н-индол-3-ил)-1,2,3,4-тетрагидроизохинолины, способы их получения, комбинаторная библиотека и фокусированная библиотека
BRPI0912871A2 (pt) * 2008-05-19 2015-10-20 Actelion Pharmaceuticals Ltd novas tetraidroisoquinolinas como agentes antimaláricos.
GB0820856D0 (en) 2008-11-14 2008-12-24 Univ Leuven Kath Novel inhibitors of flavivirus replication

Also Published As

Publication number Publication date
BR112014004437A8 (pt) 2018-01-23
CN103930404A (zh) 2014-07-16
BR112014004437B1 (pt) 2021-12-14
ME02908B (me) 2018-10-20
RS56544B1 (sr) 2018-02-28
US20140235593A1 (en) 2014-08-21
CN103930404B (zh) 2016-08-24
BR112014004437A2 (pt) 2017-03-28
HUE034721T2 (hu) 2018-02-28
SMT201700528T1 (it) 2018-01-11
DK2748147T3 (da) 2017-11-13
EP2748147B1 (en) 2017-08-02
EP2748147A1 (en) 2014-07-02
ES2644082T3 (es) 2017-11-27
PT2748147T (pt) 2017-11-14
US9416124B2 (en) 2016-08-16
WO2013027196A9 (en) 2013-04-18
JP6035334B2 (ja) 2016-11-30
WO2013027196A1 (en) 2013-02-28
LT2748147T (lt) 2017-10-25
JP2014524464A (ja) 2014-09-22
PL2748147T3 (pl) 2018-01-31
HK1199443A1 (en) 2015-07-03
CA2846507A1 (en) 2013-02-28
CA2846507C (en) 2020-03-10
HRP20171567T1 (hr) 2017-11-17
SI2748147T1 (sl) 2017-11-30

Similar Documents

Publication Publication Date Title
CY1124988T1 (el) Μεθοδοι παρασκευης νεων αναστολεων idh1
CY1124311T1 (el) Παρεμποδιστες dna-pk
CY1122832T1 (el) Σουλφονυλουριες και σχετικες ενωσεις και χρηση αυτων
CY1122266T1 (el) Ενωσεις 3-αμινοκυκλοαλκυλιου ως ror-gamma-t αναστολεις και χρησεις αυτων
CY1123164T1 (el) Διεργασια για τη συνθεση ενος αναστολεα ινδολαμινης 2,3-διοξυγενασης
CY1119748T1 (el) Υποκατασταθεντα 2-αλκυλ-1-οξο-ν-φαινυλ-3-ετεροαρυλ-1,2,3,4-τετραϋδροϊσοκινολιν-4-καρβοξαμιδια για ανθελονοσιακες θεραπειες
CY1118744T1 (el) Υποκατεστημενες τρικυκλικες ενωσεις ως αναστολεις fgfr
CY1120556T1 (el) Δικυκλικα ετεροκυκλα ως αναστολεις fgfr
CY1119476T1 (el) Αναστολεις της απομεθυλασης ιστονης
CY1122350T1 (el) Μεθοδος παρασκευης ινγενολ-3-αγγελικου
CY1119199T1 (el) Αναστολεις cdc7
CY1121804T1 (el) Καινοτομες ενωσεις πυριμιδινης και πυριδινης και η χρηση τους
CY1120517T1 (el) Διαρυλικες ενωσεις χρησιμες για την αγωγη ανθρωπινων νοσων στην ογκολογια, νευρολογια και ανοσολογια
CY1120438T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει μυο-ινοσιτολη και d-κιρο-ινοσιτολη
CY1118681T1 (el) Αναστολεις νεπριλυσινης
CY1117565T1 (el) Συνενωμενο δικυκλικο παραγωγο 2,4-διαμινοπυριδινης ως διπλος αναστολεας alk και fak
CY1115585T1 (el) Κρυσταλλικες μορφες του αλατος του νατριου της 5-αμινο-2,3-διυδροφθαλαζιν-1,4-διονης, οι οποιες περιεχουν φαρμακευτικα σκευασματα και διαδικασιες για την παρασκευη τους
CY1120204T1 (el) Αμορφη στερεα διασπορα για χρηση σε θεραπεια καρκινου του εγκεφαλο
CY1118416T1 (el) Υποκατεστημενες 4-φαινυλο-πυριδινες για τη θεραπεια ασθενειων που σχετιζονται με τον νκ-1 υποδοχεα
CY1118362T1 (el) Ανταγωνιστες υποδοχεων cgrp αζαϊνδανιου καρβοξαμιδιου πιπεριδινονης
CY1117955T1 (el) Αμιδινο-υποκατεστημενες ενωσεις βητα-λακταμης, παρασκευη και χρηση τους ως αντιβακτηριακοι παραγοντες
CL2016002072A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
CY1123216T1 (el) Αναστολεις της gls1 για την αντιμετωπιση νοσων
CY1123056T1 (el) Νεα μορφη χορηγησης της ρασεκαδοτριλης
EA201290642A1 (ru) Соединения и способы